| Trial ID: | L0276 |
| Source ID: | NCT01165567
|
| Associated Drug: |
Sarpogrelate
|
| Title: |
The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: sarpogrelate
|
| Outcome Measures: |
Primary: incidence of contrast-induced nephropathy, The primary outcome of the study is the incidence of CIN, defined as either a greater than 25 percent increase of serum Cr or an absolute increase in serum Cr of 0.5 mg/dL within 48 hours after using a contrast agent, within 48 hours after using a contrast agent | Secondary: occurrence of CIN, Clinical endpoint measurements are conducted in-hospital and at 4 weeks. Cr concentration is measured at admission, every day for the next two days after contrast exposure, and at 4 weeks, at 4 weeks after using a contrast agent
|
| Sponsor/Collaborators: |
Sponsor: Seoul National University Boramae Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
212
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2009-12
|
| Completion Date: |
2010-12
|
| Results First Posted: |
|
| Last Update Posted: |
2010-07-20
|
| Locations: |
Seoul National University Hospital, Seoul, 156-707, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01165567
|
